Abstract
Background Drug-related cue-reactivity, dysfunctional negative emotion processing, and response-disinhibition constitute three core aspects of methamphetamine use disorder (MUD). These phenomena have been studied independently, but the neuroscientific literature on their interaction in addictive disorders remains scant.
Methods fMRI data were collected from 62 individuals with MUD when responding to the geometric Go or No-Go cues superimposed over blank, neutral, negative-emotional and drug-related background images. Neural correlates of drug and negative-emotional cue-reactivity, response-inhibition, and response-inhibition during drug and negative-emotional blocks were estimated, and methamphetamine cue-reactivity was compared between MUDs and 23 healthy controls (HCs). Relationships between clinical and behavioral characteristics and observed activations were subsequently investigated.
Results MUDs had longer reaction times and more errors in drug and negative-emotional blocks compared to neutral and blank ones. MUDs showed higher drug cue-reactivity than HCs across prefrontal regions, fusiform gyrus, and visual cortices (Z>3.1, p-corrected<0.05). Response-inhibition was associated with activations in the precuneus, inferior parietal lobule, and anterior cingulate, temporal and inferior frontal gyri (Z>3.1, p-corrected<0.05). Response-inhibition in drug cue blocks coincided with higher activations in the visual cortex and lower activations in the paracentral lobule and superior and inferior frontal gyri, while inhibition during negative-emotional blocks led to higher superior parietal, fusiform, and lateral occipital activations (Z>3.1, p-corrected<0.05).
Conclusion Higher visual cortical activations and lower parietal and prefrontal activations during drug-related response-inhibition suggest the down-regulation of inhibitory regions and up-regulation of bottom-up drug cue-reactivity. Our results suggest that drug and negative-emotional cue-reactivity influence response-inhibition, and the study of these interactions may aid mechanistic understandings of addiction and biomarker discovery.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by Tehran University of Medical Sciences.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the ethical review board of the Tehran University of Medical Sciences with the approval code 93-02-98-23869.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Anonymized data for this manuscript is available upon request from the corresponding author.
